A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma is a phase 3 interventional study registered as NCT05888493 by Novartis Pharmaceuticals, with 109 participants enrolled, started 2023-10-02 and due to reach its primary completion in 2028-07-25. Interventions recorded: Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles, Lymphodepleting chemotherapy, Corticosteroids and/or Radiation (Bridging therapy). Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.